Image Credit: Scientific Frontline
Scientific Frontline: Extended "At a Glance" Summary: MitoCatch
The Core Concept: MitoCatch is an advanced cellular delivery system designed to transplant healthy donor mitochondria directly into diseased or damaged cells. It acts as a targeted therapy to restore vital energy management in cells suffering from mitochondrial dysfunction.
Key Distinction/Mechanism: While traditional mitochondrial transplantation is inefficient and lacks precision in targeting, MitoCatch utilizes engineered docking proteins to act as cellular "match-makers." By precisely adjusting these proteins, the system guarantees that donor mitochondria bind exclusively to the correct target cell type and enter it, remaining fully functional to move, fuse, and divide.
Major Frameworks/Components:
- MitoCatch-C: Equips target cells with docking proteins on their surface ex vivo so new mitochondria can attach and be absorbed before the cells are returned to the organism.
- MitoCatch-M: Modifies the donor mitochondria directly with docking proteins to guide them to unmodified target cells.
- MitoCatch-Bi: Utilizes a bispecific docking protein that acts as a bridge, connecting completely unaltered donor mitochondria to unaltered target cells.
Branch of Science: Molecular Biology, Cell Biology, Neuroscience, and Mitochondrial Medicine.
Future Application: The technology offers a viable therapeutic pathway for previously untreatable conditions rooted in mitochondrial dysfunction. Specific applications include treating neurodegenerative disorders such as Parkinson’s disease, repairing optic nerve degeneration, addressing certain forms of heart failure, and promoting the regeneration of retinal ganglion cells after injury.
Why It Matters: Mitochondrial dysfunction is the root cause of numerous severe and currently untreatable diseases. MitoCatch overcomes the long-standing biological obstacle of targeted delivery without triggering a detectable immune response, effectively revolutionizing the field of precision mitochondrial medicine and improving the survival and regeneration of degenerating neurons.
In many diseases, dysfunctional mitochondria play a central role. These small structures supply cells with energy. Researchers have now developed the system MitoCatch, which delivers healthy donor mitochondria specifically to the cells that need them most urgently.
Mitochondrial dysfunction is at the root of many currently untreatable diseases. These include neurodegenerative diseases such as Parkinson’s, degeneration of the optic nerve, and certain forms of heart failure. While researchers have experimented with transplanting healthy mitochondria into damaged cells, traditional methods are often inefficient. They also cannot guarantee that the new mitochondria reach the places where they are most urgently needed.
In the journal Nature, researchers led by Prof. Dr. Botond Roska at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and the University of Basel have reported on a new technology called MitoCatch. This technology enables mitochondria from healthy donors to be introduced specifically into cells that are most severely affected by disease.
Match-maker for mitochondria and cells
The MitoCatch system is based on engineered docking proteins that guide mitochondria specifically into the right cells. Researchers at IOB and the University of Basel have developed three different strategies for this. In MitoCatch-C, the target cells are equipped with docking proteins on the cell surface so that the new mitochondria can attach to them and be taken into the cell. However, this requires modifying the target cells outside the body and then returning them to the organism.
With the MitoCatch-M approach, this is not necessary. In this case, the donor mitochondria are modified instead. They are given docking proteins that guide them to the right target cells and allow them to attach only there. In the third variant, MitoCatch-Bi, both the target cells and the donor mitochondria remain unchanged. Instead, a bispecific docking protein serves as a bridge that connects the mitochondria to the cell surface. By specifically adjusting these docking proteins, researchers can control how efficiently and selectively mitochondria reach different cell types.
Temurkhan Ayupov and Dr. Verónica Moreno-Juan, co-first authors, and their colleagues tested the system in various cell types from both mice and humans. It showed that MitoCatch reliably delivers mitochondria to neurons as well as retinal, heart, endothelial, and immune cells. Once inside the cell, the mitochondria remain functional. They move, fuse, and divide, which is crucial for the normal energy management of a cell.
An approach for damaged optic nerves and retina
The research team also showed, using tissue samples from deceased patients, that donor mitochondria improve the survival of neurons from people with diseases of the optic nerve, while also promoting the regeneration of retinal ganglion cells after injury. So far, this method is well tolerated in animal models, with no detectable immune reaction.
MitoCatch opens up an entirely new approach to precision mitochondrial medicine. The technology overcomes a long-standing obstacle to delivering donor mitochondria specifically into diseased cells and could therefore revolutionize the treatment of mitochondrial diseases.
Reference material: What Is: Mitochondrion
Published in journal: Nature
Title: Cell-type-targeted mitochondrial transplantation rescues cell degeneration
Authors: Temurkhan Ayupov, Verónica Moreno-Juan, Serena Curtoni, Alex Fratzl, Upnishad Sharma, Susana Posada-Céspedes, Ramona Ratiu, Rei Morikawa, Alexandra Graff Meyer, Margherita Pezzoli, Glenn Bantug, Morgan Chevalier, Yanyan Hou, Sarah A. Nadeau, Álvaro Herrero-Navarro, Vikram Ayinampudi, Elizabeth Kastanaki, Natasha Whitehead, Rebecca A. Siwicki, Mariana M. Ribeiro, Ji Hoon Han, Annalisa Bucci, Christoph Hess, Simone Picelli, Magdalena Renner, Daniel J. Müller, Cameron S. Cowan, Simon Hansen, and Botond Roska
Source/Credit: University of Basel
Reference Number: mbio041526_01